Apixaban 2.5 mg twice daily

DRUG2 trials

Sponsors

University of Vermont, University College, London

Conditions

CancerLiver CirrhosisVTE (Venous Thromboembolism)

Phase 3

DOAC - Dosing Options in AntiCoagulation Prophylaxis

RecruitingNCT07005024

University of VermontCancer, VTE (Venous Thromboembolism)

Start: 2025-10-17End: 2035-08-01Target: 996Updated: 2026-02-05

Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial

Not yet recruitingNCT07726693

University College, LondonLiver Cirrhosis

Start: 2026-07-15End: 2031-03-30Target: 1142Updated: 2026-07-24